Krystal Biotech Inc

KRYS · Moat type: REGULIERUNG

MoatScore

10/10

Fair Value

180 USD

Margin of Safety

-102.1 %

Rating

BEOBACHTEN

Krystal Biotech develops and commercializes gene therapy products based on its proprietary HSV-1 vector platform, with commercial focus on VYJUVEK (beremagene geperpavec), the first topically applied gene therapeutic for treatment of the hereditary disease dystrophic epidermolysis bullosa (DEB).

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.